16.56
-0.49 (-2.87%)
| Penutupan Terdahulu | 17.05 |
| Jumlah Dagangan | 1,220,578 |
| Harga / Pendapatan (P/E Ke hadapan) | 189.56 |
| Harga / Jualan (P/S) | 1.09 |
| Harga / Buku (P/B) | 8.81 |
| Julat 52 Minggu |
| Margin Keuntungan | -18.71% |
| Margin Operasi (TTM) | -14.71% |
| EPS Cair (TTM) | -2.79 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 22.30% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 320.75% |
| Nisbah Semasa (MRQ) | 2.30 |
| Aliran Tunai Operasi (OCF TTM) | 13.94 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 67.48 M |
| Pulangan Atas Aset (ROA TTM) | -6.17% |
| Pulangan Atas Ekuiti (ROE TTM) | -92.31% |
Sentimen Berita
-
Tandem wins FDA clearance for tubeless automated insulin delivery system
3 hari lalu, 5:48AM
-
Tandem Diabetes stock jumps 8% on FDA clearance for tubeless pump
6 hari lalu, 9:11AM
-
Tandem Mobi Now FDA Cleared as World’s First and Only Tubeless AID System with up to Seven Days of Wear
6 hari lalu, 7:30AM
AISkor Stockmoo
| Nilai 30% | -3.3 |
| Pulangan di bawah kos modalnya. Pulangan atas modal menurun. info | |
| Hutang tinggi. Keuntungan lemah. Kecairan jangka pendek mencukupi. Aliran tunai positif. info | |
| Daripada penilaian laporan AI Insight kami tentang pulangan dijangka berbanding risiko. info | NA |
| Penilaian Relatif info | NA |
| Pertumbuhan Tersirat info | NA |
| Sejarah Penilaian info | NA |
| Nilai Pegangan info | NA |
| Premium Risiko info | NA |
| Penilaian Pasaran info | NA |
| Masa 30% | -1.7 |
| Tiada aliran jelas sepanjang tahun lalu. Jauh di bawah paras tertinggi 52 minggu. info | |
| Aliran menurun, tetapi purata bergeraknya telah mendatar. info | |
| Daripada analisis teknikal AI kami terhadap carta. info | NA |
| Corak Lilin info | NA |
| Sentimen 20% | 0.9 |
| Tiada harga sasaran terkini, jadi berdasarkan arah semakan harga sasaran. info | |
| Berita terkini kebanyakannya positif. info | |
| Sentimen Pegangan info | NA |
| Wang Pintar 20% | 0.9 |
| Beberapa orang dalam menjual bersih baru-baru ini. info | |
| Institusi bersih +8.37% daripada saham dalam pemfailan 13F terkini: 140 pemegang menambah, 137 mengurang (suku berakhir 30 Sep 2026). info | |
| Kedudukan jual singkat +37.6% dari 31 Aug hingga 30 Oct 2026, 7.6 hari untuk tutup (FINRA). info | |
| Keadaan pasaran dan sektor lemah. | |
| Persekitaran pasaran berhati-hati. info | |
| Sektor ketinggalan berbanding pasaran. | |
| Tonggak-tonggak sependapat, jadi skor diperkukuh. | |
| Tidak dikira dalam skor | |
| Hampir dengan garis aliran jangka sederhana. info | |
| Harga rendah berbanding purata 52 minggunya. Turun dalam tempoh 5 tahun. info | |
| Momentum jangka pendek menurun. info | |
| Harga hampir dengan paras sokongan. info | |
| Skor Akhir | -1.36 |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Medical Devices (US) | Bercampur | Bercampur |
| Medical Devices (Global) | Bercampur | Bercampur | |
| Stok | Tandem Diabetes Care, Inc. | Bercampur | Menaik |
Saham Serupa
| Stok | Modal Pasaran | DY | P/E (TTM) | P/B | Skor |
|---|---|---|---|---|---|
| TNDM | - | - | - | 8.81 | -1.4 |
| BWAY | - | - | - | 4.62 | 0.4 |
| SSII | - | - | - | 6.11 | -2.0 |
| QTI | - | - | - | 9.14 | -5.0 |
| AXGN | - | - | - | 6.12 | 0.0 |
| ESTA | - | - | - | 128.59 | -1.7 |
|
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for individuals with diabetes. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on Tobi (a tubeless version of Mobi), and the Sigi tubeless patch pump. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one-third is from disposable infusion sets that need to be changed over every 2 to 3 days. |
|
| Sektor | Healthcare |
| Industri | Medical Devices |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 0.95% |
| % Dimiliki oleh Institusi | 110.87% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| First Light Asset Management, Llc | 30 Sep 2026 | 3,251,835 |
| Gw&K Investment Management, Llc | 30 Sep 2026 | 2,903,529 |
| Longaeva Partners L.P. | 30 Sep 2026 | 2,358,636 |
| Ubs Group Ag | 30 Sep 2026 | 2,196,689 |
| Exoduspoint Capital Management, Lp | 30 Sep 2026 | 2,079,371 |
| Millennium Management Llc | 30 Sep 2026 | 2,070,772 |
| Paradice Investment Management Llc | 30 Sep 2026 | 2,007,415 |
| Jennison Associates Llc | 30 Sep 2026 | 1,903,283 |
| Jacobs Levy Equity Management, Inc | 30 Sep 2026 | 1,890,510 |
Tiada data dalam julat masa ini.
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| BEAVER SANDRA | - | - | 0 | 0 |
| CARPENTER RICK | - | 20.07 | -1,276 | -25,609 |
| GASSER ELIZABETH ANNE | - | 20.07 | -1,618 | -32,473 |
| HANSEN SHANNON MARIE | - | 20.07 | -1,535 | -30,807 |
| KYRILLOS JEAN-CLAUDE | 18.48 | 20.07 | -328 | -6,912 |
| MORRISON SUSAN | - | 20.07 | -810 | -16,257 |
| SHERIDAN JOHN F | - | 20.07 | -8,100 | -162,567 |
| VOSSELLER LEIGH | - | 20.07 | -1,479 | -29,684 |
| Jumlah Keseluruhan Kuantiti Bersih | -15,146 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -304,309 | |||
| Purata Pembelian Keseluruhan ($) | 18.48 | |||
| Purata Jualan Keseluruhan ($) | 20.07 | |||
| Julat Insider ($) | ||||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| KYRILLOS JEAN-CLAUDE | Pegawai | 16 Nov 2026 | Diperolehi (+) | 207 | 18.48 | 3,825 |
| BEAVER SANDRA | Pengarah | 15 Nov 2026 | Pelaksanaan pilihan | 6,747 | - | - |
| CARPENTER RICK | Pegawai | 15 Nov 2026 | Dibuang (-) | 1,276 | 20.07 | 25,609 |
| CARPENTER RICK | Pegawai | 15 Nov 2026 | Pelaksanaan pilihan | 2,506 | - | - |
| GASSER ELIZABETH ANNE | Pegawai | 15 Nov 2026 | Dibuang (-) | 1,618 | 20.07 | 32,473 |
| GASSER ELIZABETH ANNE | Pegawai | 15 Nov 2026 | Pelaksanaan pilihan | 3,014 | - | - |
| HANSEN SHANNON MARIE | Pegawai | 15 Nov 2026 | Dibuang (-) | 1,535 | 20.07 | 30,807 |
| HANSEN SHANNON MARIE | Pegawai | 15 Nov 2026 | Pelaksanaan pilihan | 3,014 | - | - |
| KYRILLOS JEAN-CLAUDE | Pegawai | 15 Nov 2026 | Dibuang (-) | 535 | 20.07 | 10,737 |
| KYRILLOS JEAN-CLAUDE | Pegawai | 15 Nov 2026 | Pelaksanaan pilihan | 1,009 | - | - |
| MORRISON SUSAN | Pegawai | 15 Nov 2026 | Dibuang (-) | 810 | 20.07 | 16,257 |
| MORRISON SUSAN | Pegawai | 15 Nov 2026 | Pelaksanaan pilihan | 2,828 | - | - |
| SHERIDAN JOHN F | Pengarah | 15 Nov 2026 | Dibuang (-) | 8,100 | 20.07 | 162,567 |
| SHERIDAN JOHN F | Pengarah | 15 Nov 2026 | Pelaksanaan pilihan | 15,917 | - | - |
| VOSSELLER LEIGH | Pegawai | 15 Nov 2026 | Dibuang (-) | 1,479 | 20.07 | 29,684 |
| VOSSELLER LEIGH | Pegawai | 15 Nov 2026 | Pelaksanaan pilihan | 4,119 | - | - |
| Papar semua | ||||||
Institusi
Pemilikan institusi: 128.77%
| Kedudukan | Pemegang | Saham |
|---|---|---|
| Bertambah | 140 | 17,373,437 |
| Berkurang | 137 | 14,384,953 |
| Baharu | 42 | 6,940,860 |
| Dijual habis | 46 | 4,068,138 |
Pemfailan SEC 13F melalui Nasdaq, pemfailan terkini hingga 30 Sep 2026. Pemfailan tiba sehingga 45 hari selepas setiap suku.
Kedudukan Jual Singkat
| Penyelesaian | Saham | Hari untuk tutup |
|---|---|---|
| 30 Oct 2026 | 16,171,009 | 7.6 |
| 15 Oct 2026 | 15,086,560 | 6.9 |
| 30 Sep 2026 | 13,369,091 | 5.2 |
| 15 Sep 2026 | 12,474,385 | 7.9 |
| 31 Aug 2026 | 11,753,819 | 8.2 |
| 14 Aug 2026 | 10,585,732 | 3.9 |
Data jual singkat FINRA melalui Nasdaq, dilaporkan dua kali sebulan.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 18 Nov 2026 | Yahoo Finance |
Tandem Diabetes shares climb 5% after Stifel upgrades stock to Buy
Investing.com -- Shares of Tandem Diabetes Care Inc (NASDAQ:TNDM) climbed 5.1% in premarket trading on Wednesday after Stifel upgraded the medical device maker to Buy from Hold, pointing to an improving margin trajectory and upcoming product catalysts. Analyst Jonathan Block also lifted his price… |
| 18 Nov 2026 | Yahoo Finance |
Insulet downgraded, Tandem Diabetes upgraded: Wall Street's top analyst calls
Insulet downgraded, Tandem Diabetes upgraded: Wall Street's top analyst calls… |
| 16 Nov 2026 | Yahoo Finance |
Tandem wins FDA clearance for tubeless automated insulin delivery system
The clearance tees up a 2027 launch of a product that analysts called Tandem’s “single most important commercial catalyst and growth driver.” |
| 13 Nov 2026 | Yahoo Finance |
Tandem Diabetes stock jumps 8% on FDA clearance for tubeless pump
Investing.com -- Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM) rose 8% after the company announced U.S. Food and Drug Administration clearance for its Tandem Mobi insulin pump to operate as a tubeless automated insulin delivery system with up to seven days of wear. |
| 13 Nov 2026 | Yahoo Finance |
Tandem Mobi Now FDA Cleared as World’s First and Only Tubeless AID System with up to Seven Days of Wear
SAN DIEGO, November 13, 2026--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a global insulin delivery and diabetes technology company, today announced U.S. Food and Drug Administration (FDA) clearance of Tandem Mobi for use as the world’s first and only tubeless automated insulin delivery system with… |
| 13 Nov 2026 | Yahoo Finance |
Can Tandem Diabetes Care (TNDM) Stay Cheap After Its Recall?
Tandem Diabetes Care has been through a bruising stretch, with the share price down about 87.2% over the past five years, and yet the business still commands meaningful attention in insulin pump therapy. With that kind of long term decline and fresh headlines around its devices, the question now is… |
| 12 Nov 2026 | Yahoo Finance |
Tandem Diabetes Care Receives Multiple Health Canada Approvals for t:slim X2 Insulin Pump
SAN DIEGO, November 12, 2026--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, today announced receipt of Health Canada approval of a license amendment for the t:slim X2™ insulin pump with Control-IQ+™ automated insulin delivery (AID)… |
| 10 Nov 2026 | Yahoo Finance |
TNDM Q3 2026 deep dive: business model transition, product launches, and leadership change
Diabetes technology company Tandem Diabetes Care (NASDAQ:TNDM) reported Q3 2026 results beating Wall Street’s revenue expectations, with sales up 13.8% year on year to $283.7 million. The company expects the full year’s revenue to be around $1.08 billion, close to analysts’ estimates. Its GAAP loss… |
| 07 Nov 2026 | Yahoo Finance |
Can Tandem Diabetes Care (TNDM) Justify Its Valuation As Q3 Earnings Beat And CEO Change Land?
Tandem Diabetes Care (TNDM) is back in focus after third quarter results showed higher sales, a much smaller net loss, reaffirmed full year revenue guidance, and a planned CEO transition to Jeannette Bankes. The latest Q3 update and the CEO transition have landed against a choppy backdrop for… |
| 06 Nov 2026 | Yahoo Finance |
What Tandem Diabetes Care (TNDM) Said on Its Q3 Earnings Call
Tandem Diabetes Care (NASDAQ:TNDM) reported 14% revenue growth in the third quarter of 2026, as higher pump shipments, pharmacy pricing and international sales helped lift gross margin. The company also announced a CEO transition and signaled that a slower-than-expected shift to pharmacy distributio… |
| 06 Nov 2026 | Yahoo Finance |
Tandem Diabetes Care names next CEO
Jeannette Bankes will take over the role from John Sheridan, who will retire at the end of the year after leading the company since 2019… |
| 06 Nov 2026 | Yahoo Finance |
Tandem Diabetes Care, Inc. Q3 2026 Earnings Call Summary
Moby summary of Tandem Diabetes Care, Inc.'s Q3 2026 earnings call… |
| 06 Nov 2026 | Yahoo Finance |
Tandem (TNDM) Q3 2026 Earnings Call Transcript
Sheridan steps down as CEO while Mobi Tubeless nears FDA clearance… |
| 06 Nov 2026 | Yahoo Finance |
Tandem Diabetes Care Inc (TNDM) Q3 2026 Earnings Call Highlights: Record Revenue and Pipeline ...
Tandem Diabetes Care Inc (TNDM) posts 14% revenue growth and record pump shipments while recalibrating 2027 outlook on slower pharmacy adoption and CEO transition. |
| 06 Nov 2026 | Yahoo Finance |
Earnings Beat Raises Fresh Questions For Tandem Diabetes Care Stock
Tandem Diabetes Care reported third quarter 2026 sales of US$283.69 million and a net loss of US$7.09 million, with earnings per share loss of US$0.10, and confirmed a CEO transition to Jeannette Bankes as John Sheridan prepares to retire. The combination of higher reported sales, reduced reported… |
| Papar semua | ||
Persediaan Teknikal Sederhana
AI Analisis Teknikal
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |